GlaxoSmithKline报告说,新的卵巢癌治疗的第三阶段试验结果大有希望。 GlaxoSmithKline reports promising phase III trial results for new ovarian cancer treatment.

GlaxoSmithKline报告说,将Zejula和Jemperli合并进行的一项第三阶段试验对一线子宫颈癌产生了积极成果。 GlaxoSmithKline reported positive results from a phase III trial combining Zejula and Jemperli for first-line advanced ovarian cancer. 与标准化疗相比,治疗表明,在统计学上,与标准的化疗相比,无进展的存活率有了显著改善,尽管总体存活率没有达到统计意义。 The treatment showed a statistically significant improvement in progression-free survival compared to standard chemotherapy, though overall survival did not meet statistical significance. 该公司将继续评估并与卫生当局分享全部结果。 The company will continue to evaluate and share full results with health authorities.